胆囊癌治疗研究进展
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v6i5.10094
Abstract
胆囊癌是一种罕见但预后不良的恶性肿瘤,主要影响女性。早期通常无症状,导致大多数患者在晚期被诊断。手术切除是早期治疗的主要手段,但晚期患者的手术效果有限。放疗在某些情况下可作为辅助治疗。化疗在晚期患者中的应用效果有限。靶向治疗的研究逐渐增多,针对HER2/neu等特定靶点的药物正在开发中,显示出潜在的治疗希望。综合多种治疗手段的个体化管理是未来的研究方向。
Keywords
胆囊癌；手术治疗；辅助治疗
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Sung H,Ferlay J,Siegel RL,etal.Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] Huang J,Lucero-Prisno DE,Zhang L,etal.Updated epide miology of gastrointestinal cancers in East Asia[J]. Nat Rev Gastroenterol Hepatol,2023,20(5):271-287.
[3] Ugai T, Sasamoto N, Lee HY, et al. Is early-onset cancer an emerg ing global epidemic current evidence and future implications[J].Nat Rev Clin Oncol,2022,19(10):656-673.
[4] Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J(En gl),2022,135(5):584-950.
[5] Roa I, Ibacache G, Munoz S, et al. Gallbladder cancer in Chile: Pathologic characteristics of survival and prognostic factors: analysis of 1,366 cases[J].Am J Clin Pathol,2014,141
[6] Roa JC, Garcia P, Kapoor VK, et al. Gallbladder cancer[J]. Nat Rev Dis Primers,2022,8(1):69.
[7] Javle M, Zhao H, Abou-Alfa GK. Systemic therapy for gallbladder cancer[J].Chin Clin Oncol,2019,8(4):44.
[8] Lee SE, Kim KS, Kim WB, et al. Practical guidelines for the sur gical treatment of gallbladder cancer[J]. J Korean Med Sci,2014,29(10):1333-1340.
[9] 刘奔,姚清扬,肖玉婷,等.基于倾向性评分匹配腹腔镜胆囊切除术治疗Tis~T2a期胆囊癌的安全性及疗效分析[J].中华肝胆外科杂志,2022,28(7):520-524.
[10] 庞芳宁,白槟,杨鹏,等.肿瘤标志物CEA、CA199、CA125联合检测对胃癌筛查价值及与TNM分期的关系[J].陕西医学杂志,2020,49(8):1040-1044.
[11] 吴飞飞.胆囊癌患者给予精准胆道外科技术与传统手术治疗的效果比较[J].按摩与康复医学,2021,12(6):60-61.
[12] 温志坚,陈战,闫兴洲,等.三维可视化技术在BismuthCorletteⅢ、Ⅳ型肝门部胆管癌计划性肝切除中的应用[J].武警医学,2021,32(3):218-223.
[13] Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis[J].J Clin Oncol,2012,30(16):1934-1940.
[14] Yashima Y, Sato S, Kawai T, et al. Intraarterial 5-fluo rouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma[J]. Hepatol Int, 2015,9(1):142-148.
[15] Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary tract cancer(BINGO):a randomised,open-label, non comparative phase 2 trial[J].Lancet Oncol,2014,15(8):819-828.
[16] Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gem citabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med,2010,362(14):1273-1281.
[17] 全志伟,汤朝晖,庄鹏远.晚期胆囊癌化疗新方案有效性、安全性的随机、对照、开放、多中心临床研究[J].中华肝胆外科杂志,2010,16(11):809-811.
[18] QuanZW,YangY,LiJY,etal.Themechanisms of so matostatin induced enhanced chemosensitivity of gall bladder cancer cell line to doxorubicin: cell cycle modu lation plus target enzyme up-regulation[J].Biomed Phar macother,2010,64(7):451-457.
[19] Wang SJ, Lemieux A, Kalpathy-Cramer J, et al. Nomo gram for predicting the benefit of adjuvant chemoradio ther apy for resected gallbladder cancer[J].J Clin Oncol, 2011,29 (35):4627-4632.
[20] 杨絫,冯飞灵,周海华,等.胆囊癌术后辅助性放疗的疗效分析[J].中华肿瘤杂志,2013,35(7):534-539.
[21] Wang SJ, Lemieux A, Kalpathy-Cramer J, et al. Nomo gram for predicting the benefit of adjuvant chemoradio therapy for resected gallbladder cancer[J].J Clin Oncol, 2011, 29(35):4627-4632.
[22] 张红晨,张勇,刘颖斌,等.EGFR信号通路与胆囊癌靶向治疗[J].外科理论与实践,2015,20(2):172-175.
[23] LiM,ZhangZ,LiX,etal.Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies re current mutations in the ErbB pathway[J].NatGenet,2014,46(8):872-876.
[2] Huang J,Lucero-Prisno DE,Zhang L,etal.Updated epide miology of gastrointestinal cancers in East Asia[J]. Nat Rev Gastroenterol Hepatol,2023,20(5):271-287.
[3] Ugai T, Sasamoto N, Lee HY, et al. Is early-onset cancer an emerg ing global epidemic current evidence and future implications[J].Nat Rev Clin Oncol,2022,19(10):656-673.
[4] Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J(En gl),2022,135(5):584-950.
[5] Roa I, Ibacache G, Munoz S, et al. Gallbladder cancer in Chile: Pathologic characteristics of survival and prognostic factors: analysis of 1,366 cases[J].Am J Clin Pathol,2014,141
[6] Roa JC, Garcia P, Kapoor VK, et al. Gallbladder cancer[J]. Nat Rev Dis Primers,2022,8(1):69.
[7] Javle M, Zhao H, Abou-Alfa GK. Systemic therapy for gallbladder cancer[J].Chin Clin Oncol,2019,8(4):44.
[8] Lee SE, Kim KS, Kim WB, et al. Practical guidelines for the sur gical treatment of gallbladder cancer[J]. J Korean Med Sci,2014,29(10):1333-1340.
[9] 刘奔,姚清扬,肖玉婷,等.基于倾向性评分匹配腹腔镜胆囊切除术治疗Tis~T2a期胆囊癌的安全性及疗效分析[J].中华肝胆外科杂志,2022,28(7):520-524.
[10] 庞芳宁,白槟,杨鹏,等.肿瘤标志物CEA、CA199、CA125联合检测对胃癌筛查价值及与TNM分期的关系[J].陕西医学杂志,2020,49(8):1040-1044.
[11] 吴飞飞.胆囊癌患者给予精准胆道外科技术与传统手术治疗的效果比较[J].按摩与康复医学,2021,12(6):60-61.
[12] 温志坚,陈战,闫兴洲,等.三维可视化技术在BismuthCorletteⅢ、Ⅳ型肝门部胆管癌计划性肝切除中的应用[J].武警医学,2021,32(3):218-223.
[13] Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis[J].J Clin Oncol,2012,30(16):1934-1940.
[14] Yashima Y, Sato S, Kawai T, et al. Intraarterial 5-fluo rouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma[J]. Hepatol Int, 2015,9(1):142-148.
[15] Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary tract cancer(BINGO):a randomised,open-label, non comparative phase 2 trial[J].Lancet Oncol,2014,15(8):819-828.
[16] Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gem citabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med,2010,362(14):1273-1281.
[17] 全志伟,汤朝晖,庄鹏远.晚期胆囊癌化疗新方案有效性、安全性的随机、对照、开放、多中心临床研究[J].中华肝胆外科杂志,2010,16(11):809-811.
[18] QuanZW,YangY,LiJY,etal.Themechanisms of so matostatin induced enhanced chemosensitivity of gall bladder cancer cell line to doxorubicin: cell cycle modu lation plus target enzyme up-regulation[J].Biomed Phar macother,2010,64(7):451-457.
[19] Wang SJ, Lemieux A, Kalpathy-Cramer J, et al. Nomo gram for predicting the benefit of adjuvant chemoradio ther apy for resected gallbladder cancer[J].J Clin Oncol, 2011,29 (35):4627-4632.
[20] 杨絫,冯飞灵,周海华,等.胆囊癌术后辅助性放疗的疗效分析[J].中华肿瘤杂志,2013,35(7):534-539.
[21] Wang SJ, Lemieux A, Kalpathy-Cramer J, et al. Nomo gram for predicting the benefit of adjuvant chemoradio therapy for resected gallbladder cancer[J].J Clin Oncol, 2011, 29(35):4627-4632.
[22] 张红晨,张勇,刘颖斌,等.EGFR信号通路与胆囊癌靶向治疗[J].外科理论与实践,2015,20(2):172-175.
[23] LiM,ZhangZ,LiX,etal.Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies re current mutations in the ErbB pathway[J].NatGenet,2014,46(8):872-876.
Copyright © 2024 蔡俊杰, 汪占金, 李富源, 薛张佗, 周瀛
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
